BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 26771835)

  • 1. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.
    Muchtar E; Buadi FK; Dispenzieri A; Gertz MA
    Acta Haematol; 2016; 135(3):172-90. PubMed ID: 26771835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic challenges of amyloidosis in Waldenström macroglobulinemia.
    Palladini G; Merlini G
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):244-6. PubMed ID: 23474147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin light chain amyloidosis.
    Merlini G; Comenzo RL; Seldin DC; Wechalekar A; Gertz MA
    Expert Rev Hematol; 2014 Feb; 7(1):143-56. PubMed ID: 24350907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy.
    Cohen AD; Comenzo RL
    Hematology Am Soc Hematol Educ Program; 2010; 2010():287-94. PubMed ID: 21239808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic immunoglobulin light-chain amyloidosis.
    Comenzo RL
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):182-5. PubMed ID: 17229332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracorporeal membrane oxygenation as bridge-to-decision in acute heart failure due to systemic light-chain amyloidosis.
    Mancio Silva J; Fontes-Carvalho R; Valente D; Almeida C; Cruz AJ; Tente D; Coelho H; Oliveira M; Albuquerque A; Ribeiro VG
    Am J Case Rep; 2015 Mar; 16():174-81. PubMed ID: 25803181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic light-chain amyloidosis presenting with rapid progressive heart failure.
    Sunbul M; Durmus E; Kivrak T; Besiroglu F; Gerin F; Sari I; Mutlu B
    Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):224-7. PubMed ID: 23868674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Amyloid light chain amyloidosis].
    Suzuki K; Shimizu T
    Brain Nerve; 2014 Jul; 66(7):795-809. PubMed ID: 24998824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.
    Gertz MA; Comenzo R; Falk RH; Fermand JP; Hazenberg BP; Hawkins PN; Merlini G; Moreau P; Ronco P; Sanchorawala V; Sezer O; Solomon A; Grateau G
    Am J Hematol; 2005 Aug; 79(4):319-28. PubMed ID: 16044444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [AL Amyloidosis].
    Ueda M
    Brain Nerve; 2024 May; 76(5):583-587. PubMed ID: 38741500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New and developing therapies for AL amyloidosis.
    Zumbo G; Sadeghi-Alavijeh O; Hawkins PN; Fontana M
    Expert Opin Pharmacother; 2017 Feb; 18(2):139-149. PubMed ID: 28002971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and long-term outcome of patients with systemic immunoglobulin light-chain amyloidosis.
    Nelson LM; Gustafsson F; Gimsing P
    Acta Haematol; 2015; 133(4):336-46. PubMed ID: 25531398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.
    Gertz MA
    Am J Hematol; 2011 Feb; 86(2):180-6. PubMed ID: 21264900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
    Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
    Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
    Bellotti V; Mangione P; Merlini G
    J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis.
    Picken MM
    Contrib Nephrol; 2007; 153():135-55. PubMed ID: 17075228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.